| Literature DB >> 30347790 |
Carla Busquets-Cortés1,2, Xavier Capó3,4, Maria Del Mar Bibiloni5,6, Miquel Martorell7, Miguel D Ferrer8,9, Emma Argelich10,11, Cristina Bouzas12,13, Sandra Carreres14,15, Josep A Tur16,17, Antoni Pons18,19, Antoni Sureda20,21.
Abstract
Regular physical activity prescription is a key point for healthy aging and chronic disease management and prevention. Our aim was to evaluate the antioxidant defense system and the mitochondrial status in peripheral blood mononuclear cells (PBMCs) and the level of oxidative damage in plasma in active, intermediate and inactive elderly. In total, 127 healthy men and women >55 years old participated in the study and were classified according on their level of declared physical activity. A more active lifestyle was accompanied by lower weight, fat mass and body mass index when compared to a more sedentary life-style. Active participants exhibited lower circulating PBMCs than inactive peers. Participants who reported higher levels of exercise had increased antioxidant protein levels when compared to more sedentary partakers. Carbonylated protein levels exhibited similar behavior, accompanied by a significant raise in expression of cytochrome c oxidase subunit IV in PBMCs. No significant changes were found in the activities of antioxidant enzymes and in the expression of structural (MitND5) and mitochondrial dynamic-related (PGC1α and Mitofusins1/2.) proteins. Active lifestyle and daily activities exert beneficial effects on body composition and it enhances the antioxidant defenses and oxidative metabolism capabilities in PBMCs from healthy elderly.Entities:
Keywords: PBMCs; ROS; active lifestyle; antioxidants; daily habits; elderly; healthy aging; mitochondria
Mesh:
Substances:
Year: 2018 PMID: 30347790 PMCID: PMC6213342 DOI: 10.3390/nu10101555
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Primer sequence and conditions used in Real-Time PCRs.
| Gene | Primer | Temp. of Annealing | |
|---|---|---|---|
| PGC-1α | Fw: | 5′-CACTTACAAGCCAAACCAACAACT-3′ | 60 °C |
| Rv: | 5′-CAATAGTCTTGTTCTCAAATGGGGA-3′ | ||
| COXIV | Fw: | 5′-AGAAGCACTATGTGTACGGCCC-3′ | 63 °C |
| Rv: | 5′-GGTTCACCTTCATGTCCAGCAT-3′ | ||
| MitND5 | Fw: | 5′-CGGCTGAGAGGGCGTAGG-3′ | 63 °C |
| Rv: | 5′-GATGAAACCGATATCCGGCCGA-3′ | ||
| Mtf1 | Fw: | 5′-TGT TTT GGT CGC AAA CTC TG-3′ | 60 °C |
| Rv: | 5′-CTG TCT GCG TAC GTC TTC CA-3′ | ||
| Mtf2 | Fw: | 5′-ATG CAT CCC CAC TTA AGC AC-3′ | 60 °C |
| Rv: | 5′-CCA GAG GGC AGA ACT TTG TC-3′ | ||
Fw: Forward; Rv: Reverse; PGC-1α, Peroxisome Proliferator-Activated Receptor Gamma Coactivator; COXIV, cytochrome c oxidase subunit IV; MitND5, Mitochondrial NADH Dehydrogenase Subunit 5; Mtf 1, Mitofusin 1; Mtf2, mitofusin 2.
Characteristics of the participants.
| Women | Men | ||||||
|---|---|---|---|---|---|---|---|
| ( | ( | ||||||
| Inactive | Intermediate | Active | Inactive | Intermediate | Active | ||
| ( | ( | ( | ( | ( | ( | ANOVA | |
| Age (years) | 67.2 ± 1.1 | 67.0 ± 0.8 | 68.1 ± 0.9 | 66.0 ± 1.1 | 66.9 ± 1.3 | 64.8 ± 1.1 $ | G |
| Weight (kg) | 68.6 ± 1.1 | 64.8 ± 0.8 | 64.1 ± 0.9 | 83.4 ± 1.1 $ | 80.4 ± 1.3 $ | 77.2 ± 1.1*$ | G, E |
| Height (cm) | 157.1 ± 1.1 | 156.9 ± 0.9 | 155.3 ± 1.1 | 170.5 ± 1.3 $ | 168.6 ± 1.4 $ | 169.4 ± 1.3 $ | G |
| BMI (kg/m2) | 27.8 ± 0.7 | 26.4 ± 0.8 | 26.6 ± 0.9 | 28.6 ± 0.6 | 28.2 ± 0.6 | 26.8 ± 0.6 * | E |
| Body fat (%) | 27.0 ± 1.0 | 23.9 ± 1.0 * | 23.1 ± 1.2 * | 22.9 ± 0.9 $ | 22.7 ± 1.1 | 19.2 ± 1.3 *$# | G, E |
| MET min/week | 2764 ± 183 | 5121 ± 125 * | 8234 ± 437 *# | 2605 ± 236 | 5064 ± 297 * | 9135 ± 567 *# | E |
Statistics: Two-way ANOVA. Results are presented as Mean ± SEM, p < 0.05. E indicates significant effects of Exercise. G indicates significant effects of Gender. * indicates significant differences between Active/Intermediate and Inactive groups. # indicates significant differences between Intermediate and Active groups. $ indicates significant differences between men and women.
Energy and nutrient intake of the participants in the study.
| Women | Men | ||||||
|---|---|---|---|---|---|---|---|
| ( | ( | ||||||
| Inactive | Intermediate | Active | Inactive | Intermediate | Active | ||
| ( | ( | ( | ( | ( | ( | ANOVA | |
| Energy | 1810.2 ± 108 | 1595.7 ± 77 | 1734.5 ± 107 | 1754.2 ± 158 | 1675.9 ± 106 | 1605.9 ± 68 | |
| Water | 2057.6 ± 123 | 2023.6 ± 130 | 1891.8 ± 109 | 2053.8 ± 157 | 2025.4 ± 144 | 2134.6 ± 150 | |
| Proteins | 16.9 ± 0.8 | 16.8 ± 0.6 | 17.2 ± 1 | 17.4 ± 1 | 19.3 ± 0.8 | 18.2 ± 0.9 | |
| Carbohydrates | 43.3 ± 2 | 45.2 ± 1 | 44.8 ± 2.1 | 46.0 ± 2 | 44.6 ± 2 | 41.9 ± 2 | |
| Lipids | 35.7 ± 2 | 33.9 ± 1 | 34.6 ± 2 | 33.5 ± 2 | 33.2 ± 2 | 35.8 ± 1 | |
| Fiber | 3.0 ± 1 | 3.2 ± 0.2 | 2.9 ± 0.3 | 3.5 ± 0.4 | 3.1 ± 0.2 | 3.2 ± 0.3 | |
| Vitamin E | 8.2 ± 0.8 | 7.5 ± 0.7 | 8.3 ± 1 | 8.6 ± 0.9 | 11.4 ± 1 | 8.4 ± 1 | |
| Vitamin C | 130 ± 17 | 140 ± 14 | 171 ± 17 | 131 ± 17 | 134 ± 17 | 137 ± 19 | |
| Selenium | 77.5 ± 11 | 75.7 ± 9 | 87,9 ± 6 | 136 ± 6 $ | 112 ± 11 $ | 124 ± 11 $ | G |
| Zinc | 7.6 ± 0.5 | 7.5 ± 0.6 | 8.1 ± 0.5 | 9.7 ± 0.6 $ | 9.5 ± 0.8 $ | 9.2 ± 0.6 $ | G |
Statistics: Mean ± SEM, p < 0.05. Two-way ANOVA. G indicates significant effects of Gender. $ indicates significant differences between men and women.
PBMC blood count.
| Women | Men | ||||||
|---|---|---|---|---|---|---|---|
| ( | ( | ||||||
| Inactive | Intermediate | Active | Inactive | Intermediate | Active | ||
| ( | ( | ( | ( | ( | ( | ANOVA | |
| PBMCs | 2.13 ± 0.13 | 1.90 ± 0.19 | 1.65 ± 0.19 * | 1.99 ± 0.19 | 1.91 ± 0.2 | 1.33 ± 0.2 * | E |
| Lymphocytes (%) | 33.2 ± 1.5 | 33.5 ± 1.3 | 32 ± 1.2 | 34 ± 1.2 | 33 ± 1.6 | 32 ± 1.1 | |
| Monocytes (%) | 6.6 ± 0.4 | 7.3 ± 0.4 | 6.5 ± 0.3 | 7.3 ± 0.4 | 7.6 ± 0.4 | 6.6 ± 0.3 | |
Statistics: Two-way ANOVA. Results are presented as Mean ± SEM, p < 0.05. E indicates significant effects of Exercise. * indicates significant differences between Active/Intermediate and Inactive groups.
Peripheral blood mononuclear cells (PBMCs) protein levels.
| Inactive | Intermediate | Active | ANOVA | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G | E | SxE | |||||||||||
| CAT (%) | Women | 100 | ± | 9 | 114 | ± | 13 | 146 | ± | 17 # | 0.001 | 0.013 | 0.601 |
| Men | 132 | ± | 12 | 170 | ± | 17 * | 175 | ± | 17 #$ | ||||
| MnSOD (%) | Women | 100 | ± | 10 | 116 | ± | 13 | 156 | ± | 21 # | 0.420 | 0.045 | 0.900 |
| Men | 125 | ± | 13 | 127 | ± | 20 | 162 | ± | 24 | ||||
| GRd (%) | Women | 100 | ± | 10 | 109 | ± | 10 | 165 | ± | 20 # | 0.013 | 0.000 | 0.759 |
| Men | 123 | ± | 20 | 158 | ± | 21 | 209 | ± | 24 #$ | ||||
| GPx (%) | Women | 100 | ± | 12 | 111 | ± | 14 | 168 | ± | 26 # | 0.994 | 0.002 | 0.720 |
| Men | 108 | ± | 9 | 120 | ± | 17 | 152 | ± | 21 # | ||||
| TrxR1 (%) | Women | 100 | ± | 13 | 135 | ± | 16 | 172 | ± | 24 # | 0.056 | 0.001 | 0.853 |
| Men | 124 | ± | 24 | 177 | ± | 23 * | 196 | ± | 21 # | ||||
| UCP3 (%) | Women | 100 | ± | 10 | 102 | ± | 9 | 118 | ± | 15 | 0.099 | 0.039 | 0.565 |
| Men | 112 | ± | 10 | 109 | ± | 8 | 152 | ± | 19 # | ||||
Statistics: Two-way ANOVA. Results are presented as Mean ± SEM, p < 0.05. E indicates significant effects of Exercise. G indicates significant effects of Gender. * indicates significant differences between Active/Intermediate and Inactive groups. # indicates significant differences between Intermediate and Active groups. $ indicates significant differences between men and women.
Figure 1MDA levels in plasma men and women in the study, classified according to physical activity. No significant effects of gender or exercises were found. Statistics: Two-way ANOVA. Results are presented as Mean ± SEM.
Figure 2Nitro-Tyr levels in PBMCs men and women in the study, classified according to physical activity. No significant effects of gender or exercises were found. Statistics: Two-way ANOVA. Results are presented as Mean ± SEM.
Figure 3Carbonylated protein levels in PBMCs men and women in the study, classified according to physical activity. Statistics: Two-way ANOVA. Results are presented as Mean ± SEM, p < 0.05. E indicates significant effects of exercise. # indicate differences with respect to the inactive group.
Relative mRNA expression in PBMCs.
| Women | Men | ||||||
|---|---|---|---|---|---|---|---|
| ( | ( | ||||||
| mRNA levels | Inactive | Intermediate | Active | Inactive | Intermediate | Active | |
| (%) | ( | ( | ( | ( | ( | ( | ANOVA |
| COXIV | 1 ± 0.4 | 1.39 ± 0.5 | 5.25 ± 1.9 * | 1.23 ± 0.4 | 1.53 ± 0.8 | 4.37 ± 1.9 * | E |
| PGC1α | 1 ± 0.9 | 1.11 ± 0.7 | 1.91 ± 1.0 | 1.08 ± 0.9 | 1.12 ± 0.4 | 1.19 ± 0.6 | |
| MitND5 | 1 ± 0.4 | 0.96 ± 0.5 | 0.72 ± 0.3 | 1.32 ± 0.5 | 0.57 ± 0.01 | 1.05 ± 0.4 | |
| Mtf1 | 1 ± 0.3 | 0.80 ± 0.2 | 1.55 ± 0.8 | 0.79 ± 0.3 | 1.48 ± 0.7 | 1.38 ± 0.5 | |
| Mtf2 | 1 ± 0.5 | 1.02 ± 0.7 | 1.91 ± 0.8 | 0.83 ± 0.3 | 1.13 ± 0.7 | 1.49 ± 0.6 | |
Statistics: Two-way ANOVA. E indicates significant effects of Exercise. G indicates significant effects of Gender. Results are presented as Mean ± SEM, p < 0.05. * indicates significant differences between Active/Intermediate and Inactive groups.
Enzymatic activities in PBMCs and plasma.
| Women | Men | ||||||
|---|---|---|---|---|---|---|---|
| ( | ( | ||||||
| Inactive | Intermediate | Active | Inactive | Intermediate | Active | ||
| ( | ( | ( | ( | ( | ( | ||
| PBMCs | CAT (K/109 cells) | 53 ± 24 | 44 ± 25 | 32 ± 13 | 38 ± 15 | 36 ± 18 | 71 ± 30 |
| SOD (pkat/109 cells) | 57 ± 16 | 84 ± 27 | 110 ± 31 | 71 ± 39 | 69 ± 27 | 64 ± 16 | |
| GPx (nkat/109 cells) | 102 ± 31 | 77 ± 14 | 89 ± 21 | 80 ± 29 | 95 ± 38 | 54 ± 19 | |
| GRd (nkat/109 cells) | 447 ± 174 | 406 ± 102 | 420 ± 166 | 326 ± 100 | 324 ± 67 | 303 ± 84 | |
| Plasma | CAT (K/L) | 43 ± 20 | 51 ± 15 | 54 ± 17 | 41 ± 17 | 44 ± 14 | 64 ± 14 |
| SOD (pkat/L) | 736 ± 117 | 536 ± 72 | 526 ± 76 | 724 ± 108 | 678 ± 103 | 649 ± 67 | |
Statistics: Two-way ANOVA. No significant changes between genders were found, and no effects of physical activity were detected.